Zobrazeno 1 - 10
of 544
pro vyhledávání: '"Ralf, Gutzmer"'
Autor:
Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kähler, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pföhler, Farnaz Rahimi, Beatrice Schell, Patrick Terheyden, Kai-Martin Thoms, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionDespite recent advancements in the treatment of metastatic uveal melanoma (UM), the availability of further treatment options remains limited and the prognosis continues to be poor in many cases. In addition to tebentafusp, immune checkpo
Externí odkaz:
https://doaj.org/article/e37aacd9f05d43b681af7a4bbdfeb024
Autor:
Ying Wang, Carolin Ertl, Christina Schmitt, Linda Hammann, Rafaela Kramer, Ulrich Grabmaier, Florian Schöberl, David Anz, Ignazio Piseddu, Giulia Pesch, Julio Vera, Waltraud Froehlich, Ludwig Weckbach, Dirk Tomsitz, Carmen Loquai, Lisa Zimmer, Johanna Mangana, Reinhard Dummer, Ralf Gutzmer, Kai-Christian Klespe, Henner Stege, Frank Meiss, Kai-Martin Thoms, Patrick Terheyden, Paul J. Bröckelmann, Douglas B. Johnson, Lars E. French, Lucie Heinzerling
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundImmune checkpoint inhibitor (ICI)-induced myocarditis is a rare immune-related adverse event (irAE) with a fatality rate of 40%–46%. However, irMyocarditis can be asymptomatic. Thus, improved monitoring, detection and therapy are needed.
Externí odkaz:
https://doaj.org/article/0d24ababd2e842d890215bef5ee1389e
Autor:
Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy, Rene González, Jacob Schachter, Ana M. Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett G. M. Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Joy Ge, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3165-3180 (2023)
Abstract Introduction At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). HRQoL results fr
Externí odkaz:
https://doaj.org/article/c25ae9485a674062bd066049630a8b43
Autor:
Dirk Schadendorf, Carola Berking, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Jessica Hassel, Patrick Terheyden, Henner Stege, Katharina Kaehler, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Ulrike Leiter, Markus V Heppt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Kai Christian Klespe, Michael Tronnier, Imke von Wasielewski, Felix Kieker, Christopher Gebhardt, Jan Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/85987b665cf74916884422bf2059f401
Autor:
Nora Möhn, Susann Mahjoub, Laura Duzzi, Emily Narten, Lea Grote‐Levi, Gudrun Körner, Tabea Seeliger, Gernot Beutel, Benjamin‐Alexander Bollmann, Thomas Wirth, André Huss, Hayrettin Tumani, Imke Grimmelmann, Ralf Gutzmer, Philipp Ivanyi, Thomas Skripuletz, ICOG‐CCCH (Immune Cooperative Oncology Group; Comprehensive Cancer Center Hannover)
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9373-9383 (2023)
Abstract Background Oncological patients can benefit substantially from treatment with immune checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse events (irAE). Especially ICI‐mediated neurological adverse
Externí odkaz:
https://doaj.org/article/fc59d8e698d2445d874c2607cff2f8e4
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
Mycosis fungoides and Sézary syndrome are rare and largely incurable types of cutaneous T-cell lymphoma with limited therapeutic options. In 1984 Bunn et al. reported that interferon alpha is an efficient monotherapy in cutaneous T-cell lymphoma and
Externí odkaz:
https://doaj.org/article/6cb814485e674fa2a49a3720199f8ac0
Autor:
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Julia Welzel, Daniel Robert Engel, Sophia Kreft, Antje Sucker, Georg Lodde, Frederik Krefting, Ingo Stoffels, Joachim Klode, Alexander Roesch, Lisa Zimmer, Elisabeth Livingstone, Eva Hadaschik, Jürgen C. Becker, Michael Weichenthal, Alpaslan Tasdogan, Dirk Schadendorf, Selma Ugurel
Publikováno v:
EBioMedicine, Vol 96, Iss , Pp 104774- (2023)
Summary: Background: PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one of few biomarkers predicting ICI therapy outcome. The objective of the present study was to sy
Externí odkaz:
https://doaj.org/article/2d744a8eed3741f3b79556e7478f0af0
Autor:
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, Jan Christoph Simon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these pati
Externí odkaz:
https://doaj.org/article/b02d789393944e89a582fe64cc6e6ada
Autor:
Dirk Schadendorf, Lucie Heinzerling, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Carsten Weishaupt, Jochen Utikal, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Maike Trommer, Jürgen Christian Becker, Ulrike Leiter, Cindy Franklin, Christoffer Gebhardt, Katharina Kahler, Leonie Bluhm, Imke Grimmelmann, Marlene Garzarolli, Dorothee Nashan, Michael Sachse, Julia Welzel, Gerhard Weyandt, Susanne Horn, Fabian Ziller, Harald Löffler, Stephan Grabbe, Gaston Schley, Georg Lodde, Jan-Malte Placke, Anca Sindrilaru
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 4 (2023)
Background Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival
Externí odkaz:
https://doaj.org/article/78c357556a7d4fdbba1d2ae0e5644ffc
Autor:
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
Publikováno v:
Cancers, Vol 15, Iss 18, p 4436 (2023)
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for BRAF-mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the
Externí odkaz:
https://doaj.org/article/d06b1c350906457c9e3a32544876fb20